company background image

Mangalam Drugs & Organics BSE:532637 Stock Report

Last Price


Market Cap







26 Sep, 2022


Company Financials
532637 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance2/6
Financial Health4/6

532637 Stock Overview

Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates at VAPI in India and internationally.

Mangalam Drugs & Organics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mangalam Drugs & Organics
Historical stock prices
Current Share Price₹145.15
52 Week High₹172.65
52 Week Low₹97.00
1 Month Change-1.79%
3 Month Change1.26%
1 Year Change1.50%
3 Year Change385.45%
5 Year Change-1.29%
Change since IPO352.18%

Recent News & Updates

Shareholder Returns

532637IN PharmaceuticalsIN Market

Return vs Industry: 532637 exceeded the Indian Pharmaceuticals industry which returned -13% over the past year.

Return vs Market: 532637 exceeded the Indian Market which returned 0.5% over the past year.

Price Volatility

Is 532637's price volatile compared to industry and market?
532637 volatility
532637 Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement5.8%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market3.7%

Stable Share Price: 532637 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 532637's weekly volatility (6%) has been stable over the past year.

About the Company

1972479Govardhan Dhoot

Mangalam Drugs & Organics Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates at VAPI in India and internationally. It offers a range of API products, which include Acyclovir, Amodiaquine, Artemether, Artesunate, Atorvastatin Calcium, Atazanavir Sulfate, Bisoprolol Fumarate, Chloroquine Phosphate, and Dolutegravir Sodium; Efavirenz, Emtricitabine, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, and Nimesulide; Nitrofurantoin Anhydrous and Monohydrate; Primaquine and Piperaquine Phosphate; Pregabalin, Pyrimethamine, Pyronaridine Tetraphosphate, and Sulfadoxine; and Tenofovir Alafenamide Hemifumarate and Disoproxil Fumarate. The company also offers intermediates comprising 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-Dichloro-5-methoxy pyrimidine; 4,7 Dichloroquinoline; Ortho phenoxy methane sulfonanilide; and Tenofovir Alafenamide Base and Disoproxil Base.

Mangalam Drugs & Organics Fundamentals Summary

How do Mangalam Drugs & Organics's earnings and revenue compare to its market cap?
532637 fundamental statistics
Market Cap₹2.30b
Earnings (TTM)₹182.46m
Revenue (TTM)₹4.50b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
532637 income statement (TTM)
Cost of Revenue₹3.05b
Gross Profit₹1.45b
Other Expenses₹1.27b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)11.53
Gross Margin32.23%
Net Profit Margin4.05%
Debt/Equity Ratio58.4%

How did 532637 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is 532637 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 532637?

Other financial metrics that can be useful for relative valuation.

532637 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.7x
Enterprise Value/EBITDA7.1x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 532637's PE Ratio compare to its peers?

532637 PE Ratio vs Peers
The above table shows the PE ratio for 532637 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average25.6x
532989 Bafna Pharmaceuticals
526953 Venus Remedies
524500 Kilitch Drugs (India)
500009 Ambalal Sarabhai Enterprises
532637 Mangalam Drugs & Organics

Price-To-Earnings vs Peers: 532637 is good value based on its Price-To-Earnings Ratio (12.6x) compared to the peer average (25.6x).

Price to Earnings Ratio vs Industry

How does 532637's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 532637 is good value based on its Price-To-Earnings Ratio (12.6x) compared to the Indian Pharmaceuticals industry average (23.5x)

Price to Earnings Ratio vs Fair Ratio

What is 532637's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

532637 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 532637's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 532637 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 532637 (₹145.15) is trading above our estimate of fair value (₹1.04)

Significantly Below Fair Value: 532637 is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Mangalam Drugs & Organics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mangalam Drugs & Organics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine Mangalam Drugs & Organics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Mangalam Drugs & Organics competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Mangalam Drugs & Organics performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 532637 has high quality earnings.

Growing Profit Margin: 532637's current net profit margins (4.1%) are lower than last year (6.3%).

Past Earnings Growth Analysis

Earnings Trend: 532637's earnings have grown by 7% per year over the past 5 years.

Accelerating Growth: 532637's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 532637 had negative earnings growth (-24.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.1%).

Return on Equity

High ROE: 532637's Return on Equity (12.1%) is considered low.

Discover strong past performing companies

Financial Health

How is Mangalam Drugs & Organics's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 532637's short term assets (₹1.8B) exceed its short term liabilities (₹1.3B).

Long Term Liabilities: 532637's short term assets (₹1.8B) exceed its long term liabilities (₹477.5M).

Debt to Equity History and Analysis

Debt Level: 532637's net debt to equity ratio (57.1%) is considered high.

Reducing Debt: 532637's debt to equity ratio has reduced from 67.6% to 58.4% over the past 5 years.

Debt Coverage: 532637's debt is well covered by operating cash flow (29.2%).

Interest Coverage: 532637's interest payments on its debt are not well covered by EBIT (2.8x coverage).

Balance Sheet

Discover healthy companies


What is Mangalam Drugs & Organics's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 532637's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 532637's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 532637's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 532637's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: 532637 is not paying a notable dividend for the Indian market.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 532637 has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Govardhan Dhoot (69 yo)

no data




Mr. Govardhan Murlidhar Dhoot serves as the Chairman of the Board and Managing Director at Mangalam Drugs & Organics Limited and has been its Executive Director since April 16, 1996.

CEO Compensation Analysis

Govardhan Dhoot's Compensation vs Mangalam Drugs & Organics Earnings
How has Govardhan Dhoot's remuneration changed compared to Mangalam Drugs & Organics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022₹2m₹2m


Dec 31 2021n/an/a


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021₹2mn/a


Dec 31 2020n/an/a


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020₹5m₹2m


Dec 31 2019n/an/a


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019₹2m₹2m


Dec 31 2018n/an/a


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018₹2m₹2m


Dec 31 2017n/an/a


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017₹2m₹2m


Dec 31 2016n/an/a


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016₹1m₹1m


Compensation vs Market: Govardhan's total compensation ($USD24.65K) is below average for companies of similar size in the Indian market ($USD40.31K).

Compensation vs Earnings: Govardhan's compensation has been consistent with company performance over the past year.

Board Members

Experienced Board: 532637's board of directors are considered experienced (4.6 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

BSE:532637 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Jun 22Sell₹1,282,266Govardhan DhootIndividual9,000₹142.47
02 Jun 22Sell₹1,255,819Chandrakanta DhootIndividual9,000₹139.54

Ownership Breakdown

What is the ownership structure of 532637?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders4,141,63926.2%
Private Companies5,116,69832.3%
General Public6,569,91141.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 20 shareholders own 58.49% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Shri JB Pharma LLP
2,650,000₹384.6m0%no data
Shree Kishoriju Trading & Investment Pvt. Ltd.
1,098,515₹159.4m0%no data
Shree Rasbihari Trading and Investment Pvt Ltd.
1,011,663₹146.8m0%no data
Govardhan Dhoot
677,122₹98.3m-1.31%no data
Brijmohan Dhoot
564,469₹81.9m0%no data
Chandrakanta Dhoot
421,067₹61.1m-2.09%no data
Ashutosh Taparia
302,000₹43.8m0%no data
Sanjeevkumar Taparia
300,000₹43.5m0%no data
Ajay Upadhyaya
300,000₹43.5m50%no data
Radhika Dhoot
292,500₹42.5m0%no data
Smita Dhoot
292,500₹42.5m0%no data
Rajkumari Dhoot
275,948₹40.1m0%no data
Jyotiprasad Taparia
211,291₹30.7m11.79%no data
Raj Exports Pvt Ltd
191,520₹27.8m0%no data
Ambika Food Industries Private Limited
165,000₹23.9m0%no data
Rekha Dhoot
148,760₹21.6m0%no data
Ajay Dhoot
138,687₹20.1m0%no data
Jyoti Dhoot
104,550₹15.2m0%no data
Aaditya Dhoot
89,225₹13.0m0%no data
Rajkamal Sukhani
23,520₹3.4m0%no data

Company Information

Mangalam Drugs & Organics Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Mangalam Drugs & Organics Limited
  • Ticker: 532637
  • Exchange: BSE
  • Founded: 1972
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹2.297b
  • Shares outstanding: 15.83m
  • Website:

Number of Employees


  • Mangalam Drugs & Organics Limited
  • Rupam Building
  • 3rd Floor
  • Mumbai
  • Maharashtra
  • 400001
  • India


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
532637BSE (Mumbai Stock Exchange)YesEquity SharesININRMay 2005
MANGALAMNSEI (National Stock Exchange of India)YesEquity SharesININRMay 2005

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/26 00:00
End of Day Share Price2022/09/26 00:00
Annual Earnings2022/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.